Results 51 to 60 of about 278,985 (182)
Dopamine agonists and risk: impulse control disorders in Parkinson's disease. [PDF]
, 2011 Impulse control disorders are common in Parkinson's disease, occurring in 13.6% of patients. Using a pharmacological manipulation and a novel risk taking task while performing functional magnetic resonance imaging, we investigated the relationship ...
Brezing, C. +15 more
core +1 more source
Frontiers in Neurology, 2018 Impulse control disorder (ICD), including pathological gambling, hypersexuality, and compulsive shopping has been linked to antiparkinsonian medication, especially dopamine agonists.
Pedro J. Garcia-Ruiz
doaj +1 more source
Development of novel ligands influencing neurotransmission in the central nervous system [PDF]
, 2007 The development of novel drugs targeting GPCRs is of particular interest since modulation of subfamilies of this receptor class highly influences neurotransmission in the central nervous system.
Sasse, Britta Caroline
core
Indian Journal of Endocrinology and Metabolism, 2013 Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj +1 more source
Nature and Science of Sleep, 2023 Elliott Kyung Lee,1,2 Naomi Spitale,2,3 Rebecca Robillard2 1Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada; 2Sleep Research Unit, Institute for Mental Health Research (IMHR), Ottawa, Ontario, Canada; 3Department of Medicine ...
Lee EK, Spitale N, Robillard R
doaj
Parkinson's Disease, 2012 Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists.
Carina J. Bleickardt +3 more
doaj +1 more source
Frontiers in PharmacologyBackgroundThe dopaminergic system plays a central role in motor control, goal-directed behavior, and the pathophysiology of multiple diseases including restless legs syndrome.
Jeremiah B. Joyce +2 more
doaj +1 more source
PLoS ONE, 2013 The evolution of the biogenic amine signalling system in vertebrates is unclear. However, insights can be obtained from studying the structures and signalling properties of biogenic amine receptors from the protochordate, amphioxus, which is an ...
Asha L Bayliss, Peter D Evans
doaj +1 more source
The History and Pharmacology of Dopamine Agonists [PDF]
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1984 ABSTRACTThe recognition of the dopaminergic properties of some ergot derivatives has initiated new therapeutical approaches in endocrinology as well as in neurology. The pharmacological characterization of the different ergot derivatives during the last decade has largely improved our understanding of central dopaminergic systems. Their development has
openaire +2 more sources
Nature Communications, 2018 Dopamine receptor agonists are used for the treatment of various psychiatric diseases. Here, the authors screen approximately three million compounds and identify a novel class of D1R agonists that do not have a catechol scaffold and possess promising ...
David L. Gray +12 more
doaj +1 more source